Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. (Q33871459)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

0 references

1 reference

Europe PubMed Central

Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

type 2 diabetes

1 reference

based on heuristic

inferred from title

Dario Giugliano

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Maria Ida Maiorino

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

G Bellastella

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

K Esposito

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

1 May 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

International Journal of Clinical Practice

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

65

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

602-612

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21489084%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Recruitment to a clinical trial improves glycemic control in patients with diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02619.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33871459&oldid=1985611762"